HighTower Advisors’s Kronos Bio KRON Stock Holding History

HighTower Advisors’s Portfolio KRON Stock Details KRON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-15,000	Closed	-$50K	–	3435
2022 Q3	$50K	Hold	15,000	–	–	﹤0.01%	2884
2022 Q2	$55K	Hold	15,000	–	–	﹤0.01%	2894
2022 Q1	$108K	Hold	15,000	–	–	﹤0.01%	2971
2021 Q4	$204K	Hold	15,000	–	–	﹤0.01%	2764
2021 Q3	$314K	Hold	15,000	–	–	﹤0.01%	2378
2021 Q2	$359K	Hold	15,000	–	–	﹤0.01%	2247
2021 Q1	$439K	Hold	15,000	–	–	﹤0.01%	2060
2020 Q4	$448K	Buy	+15,000	New	+$471K	﹤0.01%	1689

Other funds holding KRON

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VVA

Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

HighTower Advisors's KRON Position: Q4 2022 in Review

HighTower Advisors sold out of Kronos Bio (KRON) in Q4 2022, closing a stake of 15,000 shares — an estimated $50K sold.

HighTower Advisors first reported a position in KRON in Q4 2020 and held it in 8 quarters. The position peaked at $448K in Q4 2020. 97 funds tracked by Wall St. Rank hold KRON as of Q4 2022.

HighTower Advisors reported no remaining Kronos Bio position as of Q4 2022 after selling out during the quarter.
HighTower Advisors sold 15,000 Kronos Bio shares in Q4 2022, an estimated $50K.
HighTower Advisors first reported a position in Kronos Bio in Q4 2020 and held it in 8 quarters.
HighTower Advisors's Kronos Bio position peaked at $448K in Q4 2020.
97 funds tracked by Wall St. Rank held Kronos Bio as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.